Treatment toxicities in long-term survivors of limited small cell lung cancer.
A total of 211 patients with limited small cell lung cancer were assessed retrospectively for long-term toxicities, treatment-related deaths, and second primaries. All had received treatment with various combinations of doxorubicin, vincristine, cisplatin, lomustine, cyclophosphamide, and etoposide with or without split-course thoracic radiotherapy (4,000 cGy/10 fractions) and/or split-course prophylactic cranial irradiation (3,600 cGy/10 fractions). Sixty-eight (32%) of the patients survived longer than 1.5 years and formed the basis of this study. Debilitating pulmonary, cardiac, and neurologic toxicity was noted in 12%, 14%, and 15%, respectively, of long-term survivors. These complications were the result of aggressive combined modality therapy. Certain drugs appeared to cause additive toxicity when combined with radiation. Three patients developed new primary tumors of squamous cell origin. Attention must be directed to defining the safest way to employ aggressive combined modality treatment for these patients.
Frytak
S
S
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
Shaw
J N
JN
Lee
R E
RE
Eagan
R T
RT
Shaw
E G
EG
Richardson
R L
RL
Creagan
E T
ET
Coles
D T
DT
Jett
J R
JR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001921:Brain / Q000528:radiation effects; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000628:therapy*; D011878:Radiotherapy / Q000009:adverse effects*